Celyad SA (CYAD) Given Overweight Rating at Piper Jaffray Companies

Piper Jaffray Companies reiterated their overweight rating on shares of Celyad SA (NASDAQ:CYAD) in a research report released on Monday, October 9th. Piper Jaffray Companies currently has a $74.00 price target on the stock.

A number of other brokerages have also issued reports on CYAD. BidaskClub lowered shares of Celyad SA from a buy rating to a hold rating in a report on Tuesday, July 11th. ValuEngine raised shares of Celyad SA from a sell rating to a hold rating in a report on Thursday, June 29th.

Celyad SA (CYAD) opened at 61.51 on Monday. The company’s market capitalization is $585.88 million. The stock has a 50 day moving average of $57.43 and a 200-day moving average of $57.43. Celyad SA has a 52-week low of $16.31 and a 52-week high of $64.75.

WARNING: “Celyad SA (CYAD) Given Overweight Rating at Piper Jaffray Companies” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/20/piper-jaffray-companies-reiterates-overweight-rating-for-celyad-sa-cyad.html.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where card

A number of other brokerages have also issued reports on CYAD. BidaskClub lowered shares of Celyad SA from a buy rating to a hold rating in a report on Tuesday, July 11th. ValuEngine raised shares of Celyad SA from a sell rating to a hold rating in a report on Thursday, June 29th.

Celyad SA (CYAD) opened at 61.51 on Monday. The company’s market capitalization is $585.88 million. The stock has a 50 day moving average of $57.43 and a 200-day moving average of $57.43. Celyad SA has a 52-week low of $16.31 and a 52-week high of $64.75.

WARNING: “Celyad SA (CYAD) Given Overweight Rating at Piper Jaffray Companies” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/20/piper-jaffray-companies-reiterates-overweight-rating-for-celyad-sa-cyad.html.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply